Germany
· Delayed Price · Currency is EUR 4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of EUR 171.14 million. The enterprise value is 186.32 million.
| Market Cap | 171.14M |
| Enterprise Value | 186.32M |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 12.81M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.59% |
| Shares Change (QoQ) | +3.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 5.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 243.45 |
| PB Ratio | -27.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.06 |
| EV / Sales | 263.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.58 |
Financial Position
The company has a current ratio of 2.73
| Current Ratio | 2.73 |
| Quick Ratio | 1.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.72 |
| Interest Coverage | -18.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -54.30% |
| Return on Invested Capital (ROIC) | -62.02% |
| Return on Capital Employed (ROCE) | -100.77% |
| Revenue Per Employee | 6,960 |
| Profits Per Employee | -114,890 |
| Employee Count | 84 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.80% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.80% |
| 50-Day Moving Average | 13.22 |
| 200-Day Moving Average | 14.94 |
| Relative Strength Index (RSI) | 52.06 |
| Average Volume (20 Days) | 213 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of EUR 702,980 and -11.60 million in losses. Loss per share was -0.93.
| Revenue | 702,980 |
| Gross Profit | 489,491 |
| Operating Income | -12.03M |
| Pretax Income | -12.54M |
| Net Income | -11.60M |
| EBITDA | -11.36M |
| EBIT | -12.03M |
| Loss Per Share | -0.93 |
Balance Sheet
The company has 3.21 million in cash and 18.28 million in debt, giving a net cash position of -15.07 million.
| Cash & Cash Equivalents | 3.21M |
| Total Debt | 18.28M |
| Net Cash | -15.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -6.15M |
| Book Value Per Share | -0.48 |
| Working Capital | 3.68M |
Cash Flow
In the last 12 months, operating cash flow was -9.83 million and capital expenditures -770,211, giving a free cash flow of -10.60 million.
| Operating Cash Flow | -9.83M |
| Capital Expenditures | -770,211 |
| Free Cash Flow | -10.60M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 69.63% |
| Operating Margin | -1,711.58% |
| Pretax Margin | -1,784.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.59% |
| Shareholder Yield | -1.59% |
| Earnings Yield | -6.78% |
| FCF Yield | -6.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4basebio has an Altman Z-Score of -2.69. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.69 |
| Piotroski F-Score | n/a |